The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMW 2021 | Maintenance therapy and MRD in myeloma
Elena Zamagni, MD, PhD, University of Bologna, Bologna, Italy, outlines the role of maintenance therapy and measurable residual disease (MRD) in the treatment of patients with multiple myeloma, comparing approaches for standard-risk and high-risk patients. Dr Zamagni explains the importance of achieving MRD negativity prior to maintenance therapy in standard-risk patients, and the benefits of evaluating MRD negativity after induction in patients with high-risk myeloma. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.
